Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Schering-Plough
At entry, patients undergo HIV genotypic/phenotypic analysis. Patients continue their current antiretroviral regimen but are randomized to receive one of four doses of PEG-IFN or PEG-IFN placebo administered subcutaneously once per week until results of HIV genotyping/phenotyping are available (approximately 4 weeks). Patients who respond with a 0.5 log or greater decrease in HIV RNA at Week 4 have optimized HAART added to their ongoing PEG-IFN regimen and are followed for 24 weeks in an observational study.
Age
0–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients may be eligible for this study if they:
Have HIV levels of more than 2000 copies/ml.
Have failed their current HAART (had a significant increase in their HIV levels with HAART).
Have a CD4 cell count greater than 200 cells/microL.
Have had more than 6 months of HAART.
Have been on their current HAART for at least 6 weeks.
Agree to use an effective method of birth control during the study.
You may not be if
Patients will not be eligible for this study if they:
Have a history of a serious mental disorder.
Are allergic to interferons.
Are pregnant or breast-feeding.
Are taking certain medications such as ribavirin, hydroxyurea, and ganciclovir.
Clareo Health | Safety and Effectiveness of PEG-Intron in HIV-Infected Patients
